4.7 Review

Heart Failure With Recovered Left Ventricular Ejection Fraction JACC Scientific Expert Panel

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 76, Issue 6, Pages 719-734

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.05.075

Keywords

heart failure with recovered ejection fraction; myocardial recovery

Funding

  1. National Institutes of Health (NIH)
  2. American Heart Association
  3. Novartis
  4. Amgen
  5. AstraZeneca
  6. Thoratec Corporation (Abbott)
  7. Sanofi
  8. NIH

Ask authors/readers for more resources

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction. A growing body of evidence suggests that even among patients who experience a complete normalization of LV ejection fraction, a significant proportion will develop recurrent LV dysfunction accompanied by recurrent heart failure events. This has led to intense interest in understanding how to manage patients with heart failure with recovered ejection fraction (HFrecEF). Because of the lack of a standard definition for HFrecEF, and the paucity of clinical data with respect to the natural history of HFrecEF patients, there are no current guidelines on how these patients should be followed up and managed. Accordingly, this JACC Scientific Expert Panel reviews the biology of reverse LV remodeling and the clinical course of patients with HFrecEF, as well as provides guidelines for defining, diagnosing, and managing patients with HFrecEF. (C) 2020 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available